334 related articles for article (PubMed ID: 19914319)
81. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them.
Sosnik A; Augustine R
Adv Drug Deliv Rev; 2016 Aug; 103():105-120. PubMed ID: 26772138
[TBL] [Abstract][Full Text] [Related]
82. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.
Smit TK; Brew BJ; Tourtellotte W; Morgello S; Gelman BB; Saksena NK
J Virol; 2004 Sep; 78(18):10133-48. PubMed ID: 15331746
[TBL] [Abstract][Full Text] [Related]
83. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
84. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
Gunaseelan S; Gunaseelan K; Deshmukh M; Zhang X; Sinko PJ
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):518-31. PubMed ID: 19941919
[TBL] [Abstract][Full Text] [Related]
85. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice.
Fiandra L; Colombo M; Mazzucchelli S; Truffi M; Santini B; Allevi R; Nebuloni M; Capetti A; Rizzardini G; Prosperi D; Corsi F
Nanomedicine; 2015 Aug; 11(6):1387-97. PubMed ID: 25839392
[TBL] [Abstract][Full Text] [Related]
86. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
Sosnik A
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628
[TBL] [Abstract][Full Text] [Related]
87. Micro-Nanocarriers Based Drug Delivery Technology for Blood-Brain Barrier Crossing and Brain Tumor Targeting Therapy.
Wang L; Shi Y; Jiang J; Li C; Zhang H; Zhang X; Jiang T; Wang L; Wang Y; Feng L
Small; 2022 Nov; 18(45):e2203678. PubMed ID: 36103614
[TBL] [Abstract][Full Text] [Related]
88. Neurosymptomatic cerebrospinal fluid escape in HIV-2: a case report.
Kulkarni V; Kulkarni R; Parchure R
Int J STD AIDS; 2018 Jun; 29(7):726-728. PubMed ID: 29251118
[TBL] [Abstract][Full Text] [Related]
89. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
90. Bringing drugs into the injured brain and keeping them there.
Hermann DM; Patak P
Curr Pharm Des; 2011; 17(26):2748-9. PubMed ID: 21827401
[TBL] [Abstract][Full Text] [Related]
91. New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy.
Lenjisa JL; Woldu MA; Satessa GD
J Nanobiotechnology; 2014 Mar; 12():9. PubMed ID: 24655921
[TBL] [Abstract][Full Text] [Related]
92. Nanoparticles and Its Implications in HIV/AIDS Therapy.
Oti VB
Curr Drug Discov Technol; 2020; 17(4):448-456. PubMed ID: 31250759
[TBL] [Abstract][Full Text] [Related]
93. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.
Date AA; Destache CJ
Biomaterials; 2013 Aug; 34(26):6202-28. PubMed ID: 23726227
[TBL] [Abstract][Full Text] [Related]
94. Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS.
Singh G; Pai RS; Mustafa S
Crit Rev Ther Drug Carrier Syst; 2015; 32(6):503-33. PubMed ID: 26559551
[TBL] [Abstract][Full Text] [Related]
95. Translational research models and novel adjunctive therapies for neuroAIDS.
Zink MC
J Neuroimmune Pharmacol; 2007 Mar; 2(1):14-9. PubMed ID: 18040821
[TBL] [Abstract][Full Text] [Related]
96. Neuropharmacology.
Winston A; Manji H
Handb Clin Neurol; 2018; 152():55-64. PubMed ID: 29604984
[TBL] [Abstract][Full Text] [Related]
97. Current approaches to facilitate improved drug delivery to the central nervous system.
Markowicz-Piasecka M; Darłak P; Markiewicz A; Sikora J; Kumar Adla S; Bagina S; Huttunen KM
Eur J Pharm Biopharm; 2022 Dec; 181():249-262. PubMed ID: 36372271
[TBL] [Abstract][Full Text] [Related]
98. A review of nanocarrier-based CNS delivery systems.
Tiwari SB; Amiji MM
Curr Drug Deliv; 2006 Apr; 3(2):219-32. PubMed ID: 16611008
[TBL] [Abstract][Full Text] [Related]
99. Advancements in nano-enabled therapeutics for neuroHIV management.
Kaushik A; Jayant RD; Nair M
Int J Nanomedicine; 2016; 11():4317-25. PubMed ID: 27621624
[TBL] [Abstract][Full Text] [Related]
100. Nanomedicines for HIV therapy.
Siccardi M; Martin P; McDonald TO; Liptrott NJ; Giardiello M; Rannard S; Owen A
Ther Deliv; 2013 Feb; 4(2):153-6. PubMed ID: 23343155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
